Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly Capital Expenditures of $68000.0 in Q1 2026, up 112.5% quarter-over-quarter from $32000.0 in Q4 2025, and down 74.91% on a YoY basis from $271000.0 in Q1 2025.
Scholar Rock Holding (SRRK) Capital Expenditures (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Capital Expenditures history runs 10 years deep, the most recent figure standing at $68000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 74.91% year-over-year to $68000.0; the TTM figure through Mar 2026 stood at $399000.0 (up 12.08% YoY), while the FY2025 annual figure was $602000.0, up 514.29% from the prior year.
- Capital Expenditures was $68000.0 for Q1 2026 at Scholar Rock Holding, up from $32000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $952000.0 in Q4 2022 to a low of -$808000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $126866.7 across 5 years, with a median of $41000.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures tumbled 119.85% in 2022, then jumped 1984.62% in 2025.
- A 5-year view of Capital Expenditures shows it stood at $952000.0 in 2022, then sank by 95.69% to $41000.0 in 2023, then slumped by 46.34% to $22000.0 in 2024, then surged by 45.45% to $32000.0 in 2025, then jumped by 112.5% to $68000.0 in 2026.
- The last three Capital Expenditures figures came in at $68000.0 (Q1 2026), $32000.0 (Q4 2025), and $84000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -63,220.27 |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Jun 30, 2025 | 215,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Mar 31, 2025 | 271,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |